Emcure Pharmaceuticals Ltd

AI
Emcure Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Emcure Pharmaceuticals Ltd

₹ 2,362 2.04%
13 Nov - close price
emcure.com BSE: 544210 NSE: EMCURE
About

Incorporated in 1981, Emcure Pharmaceuticals
Ltd manufactures and markets pharmaceutical products globally[1]

Key Points

Business Overview:[1][2]
EPL develops, manufactures and markets a broad range of pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs, including chiral molecules, iron molecules and cytotoxic products. It has a presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV etc. Company has 350+ brands, with a wide network across 70+ countries.

Website BSE NSE
  • Market Cap ₹ 44,651 Cr.
  • Current Price ₹ 2,362
  • High / Low ₹ 2,430 / 1,312
  • Stock P/E 46.6
  • Book Value ₹ 216
  • Dividend Yield 0.15 %
  • ROCE 23.7 %
  • ROE 22.3 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Stock is trading at 10.9 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare Nifty MidSmallcap 400 Nifty 500 Multicap 50:25:25 BSE 500 BSE 250 SmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
888 870 903 970 1,105 1,029 1,278 1,097 1,261 1,418 1,468 1,451 1,668
788 746 796 855 947 904 1,034 869 1,036 1,118 1,096 1,111 1,272
Operating Profit 100 124 106 115 158 124 245 228 225 300 372 340 396
OPM % 11% 14% 12% 12% 14% 12% 19% 21% 18% 21% 25% 23% 24%
30 33 25 33 49 19 22 18 23 109 35 25 34
Interest 46 42 39 38 31 20 24 21 28 33 37 33 32
Depreciation 48 54 56 55 56 57 57 60 62 62 63 63 65
Profit before tax 36 61 35 55 119 67 186 166 158 314 306 269 332
Tax % 24% 20% 18% 27% 27% 25% 25% 26% 26% 18% 24% 26% 25%
27 48 29 40 87 50 140 123 118 259 234 200 248
EPS in Rs 1.51 2.67 1.60 2.23 4.60 2.65 7.37 6.48 6.20 13.65 12.33 10.55 13.10
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
2,454 2,376 3,154 3,387 3,107 3,498 4,382 5,243 6,005
1,883 1,948 2,410 2,593 2,668 3,056 3,759 4,220 4,597
Operating Profit 570 428 743 795 439 442 623 1,023 1,408
OPM % 23% 18% 24% 23% 14% 13% 14% 20% 23%
56 89 94 133 119 129 142 286 202
Interest 127 137 123 145 167 166 113 118 135
Depreciation 130 155 156 166 179 205 225 247 253
Profit before tax 370 225 557 616 212 200 428 944 1,222
Tax % 23% 22% 25% 28% 25% 20% 26% 22%
284 175 420 447 160 161 317 733 941
EPS in Rs 15.68 9.69 23.25 24.71 8.85 8.88 16.74 38.66 49.63
Dividend Payout % 16% 26% 4% 12% 23% 23% 18% 9%
Compounded Sales Growth
10 Years: %
5 Years: 11%
3 Years: 19%
TTM: 29%
Compounded Profit Growth
10 Years: %
5 Years: 12%
3 Years: 66%
TTM: 122%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 71%
Return on Equity
10 Years: %
5 Years: 16%
3 Years: 16%
Last Year: 22%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 181 181 181 181 181 181 189 190 190
Reserves 1,597 1,734 2,121 1,532 1,661 1,754 2,835 3,521 3,917
1,224 1,243 1,665 1,579 1,773 1,595 857 1,597 1,654
576 713 897 1,032 1,001 1,226 1,534 1,607 1,787
Total Liabilities 3,578 3,871 4,863 4,323 4,616 4,757 5,416 6,914 7,547
1,100 1,166 1,278 1,151 1,433 1,718 1,759 1,754 1,788
CWIP 406 326 192 239 253 106 99 122 183
Investments 311 408 864 563 690 684 678 1,424 1,658
1,761 1,971 2,529 2,369 2,240 2,248 2,880 3,614 3,918
Total Assets 3,578 3,871 4,863 4,323 4,616 4,757 5,416 6,914 7,547

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
371 385 775 428 505 585 558 424
-276 -169 -836 -394 -271 -173 -438 -947
-53 -46 31 -343 -55 -288 -49 526
Net Cash Flow 42 170 -30 -309 180 124 71 3
Free Cash Flow 85 287 677 243 225 342 378 178
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 87% 97% 120% 75% 134% 148% 100% 63%

Ratios

Standalone / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 135 175 116 109 124 115 99 107
Inventory Days 243 200 182 202 214 206 189 197
Days Payable 159 197 168 166 203 220 204 186
Cash Conversion Cycle 220 177 130 144 135 101 84 118
Working Capital Days 50 60 19 17 0 -4 61 53
ROCE % 13% 20% 21% 11% 10% 14% 24%

Insights

In beta
Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Number of Brands with Revenue > INR 100 Cr (MAT)
Count

Log in to view insights

Please log in to see hidden values.

Login
Number of Brands with Revenue > INR 50 Cr (MAT)
Count
MR Productivity (PCPM)
INR Lakh per MR per month
R&D Investment (% of Revenue from Operations)
% of revenue
Complex Products Revenue Share - India
% of India revenue
Chronic and Sub-Chronic Share of Domestic Revenue
% of domestic revenue
Field Force / MR Count (Total India)
Number of personnel
Number of Countries of Operation
Count
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
78.08% 77.94% 77.92% 77.92% 77.88% 77.87% 77.87% 77.83% 77.82%
2.91% 3.05% 3.06% 2.86% 3.29% 3.59% 3.35% 4.87% 4.94%
3.96% 3.87% 3.44% 2.84% 4.36% 6.10% 6.10% 8.46% 8.49%
15.05% 15.15% 15.58% 16.39% 14.46% 12.43% 12.69% 8.84% 8.75%
No. of Shareholders 1,52,9141,43,4491,39,6711,33,5491,26,1691,18,8631,22,1891,24,9911,29,328

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls